Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.79 USD
Change Today -0.19 / -3.82%
Volume 216.7K
As of 8:10 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

pacific biosciences of calif (PACB) Snapshot

Open
$4.88
Previous Close
$4.98
Day High
$4.98
Day Low
$4.77
52 Week High
01/13/15 - $8.78
52 Week Low
08/12/15 - $4.16
Market Cap
359.1M
Average Volume 10 Days
462.0K
EPS TTM
$-0.82
Shares Outstanding
75.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PACIFIC BIOSCIENCES OF CALIF (PACB)

pacific biosciences of calif (PACB) Related Bloomberg News

View More Bloomberg News

pacific biosciences of calif (PACB) Related Businessweek News

View More BusinessWeek News

pacific biosciences of calif (PACB) Details

Pacific Biosciences of California, Inc. designs, develops, manufactures, and markets an integrated platform for genetic analysis. The company provides single molecule real-time (SMRT) technology platform, which enables single molecule real-time detection of biological processes. It offers PacBio RS II high resolution genetic analyzer, an instrument that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company provides consumable products, which include sealed and packaged SMRT Cells, as well as various reagent kits, such as template preparation kits, binding kits, and sequencing kits to run the PacBio RS II. Its customers include research institutions, commercial laboratories, genome centers, clinical, government and academic institutions, genomics service providers, pharmaceutical companies, and agricultural companies. The company markets its products through a direct sales force in North America and Europe as well as primarily through distributors in Asia. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.

344 Employees
Last Reported Date: 03/12/15
Founded in 2000

pacific biosciences of calif (PACB) Top Compensated Officers

Executive Chairman, Chief Executive Officer a...
Total Annual Compensation: $1.0
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $1.0
Senior Vice President of Market Development
Total Annual Compensation: $399.0K
Senior Vice President of Research and Develop...
Total Annual Compensation: $399.0K
Compensation as of Fiscal Year 2014.

pacific biosciences of calif (PACB) Key Developments

Pacific Biosciences of California, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months June 30, 2015; Provides Earnings Guidance for the Third Quarter, Fourth Quarter and Full Year of 2015

Pacific Biosciences of California, Inc. reported unaudited consolidated earnings results for the second quarter and six months June 30, 2015. For the quarter, the company reported total revenue of $24,939,000 against $11,425,000 a year ago. Operating loss was $11,358,000 against $18,302,000 a year ago. Net loss was $11,935,000 or $0.16 per basic and dilute share against $19,136,000 or $0.27 per basic and diluted share a year ago. For the six months, the company reported total revenue of $42,584,000 against $23,067,000 a year ago. Operating loss was $30,686,000 against $36,547,000 a year ago. Net loss was $32,108,000 or $0.43 per basic and dilute share against $38,022,000 or $0.55 per basic and diluted share a year ago. For the third quarter, the company expects revenue will likely be lower this year compared with last year. Gross margin was higher than usual as a result of the $10 million in milestone revenue. The company expects to record a more normalized gross margin that is in the mid-30s. For the fourth quarter, the company expects to record higher gross margin again, reflecting additional milestone revenue. For the year 2015, the company expects to achieve an additional Roche milestone before the end of the year. As a result, the company increasing revenue forecast for the year, expecting annual revenue growth of at least 40%, which is up from previous forecast of at least 25% growth.

Pacific Biosciences Receives Contract for Blanket Purchase from Department of Health and Human Services

Pacific Biosciences announced contract awarded for blanket purchase agreement from Department Of Health And Human Services. The contract amount is $15,000,000.

Pacific Biosciences of California, Inc., Q2 2015 Earnings Call, Aug 05, 2015

Pacific Biosciences of California, Inc., Q2 2015 Earnings Call, Aug 05, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PACB:US $4.79 USD -0.19

PACB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Enzo Biochem Inc $2.89 USD -0.03
Fluidigm Corp $11.58 USD -0.61
NanoString Technologies Inc $14.65 USD -0.56
Sequenom Inc $2.05 USD -0.10
WaferGen Bio-systems Inc $1.08 USD -0.12
View Industry Companies
 

Industry Analysis

PACB

Industry Average

Valuation PACB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.7x
Price/Book 11.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PACIFIC BIOSCIENCES OF CALIF, please visit www.pacificbiosciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.